vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and Ramaco Resources, Inc. (METC). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $121.0M, roughly 1.2× Ramaco Resources, Inc.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs -11.0%, a 46.5% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs -27.7%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $-17.5M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs -22.7%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Ramaco Resources, Inc. is a U.S.-based mining company focused on high-grade metallurgical coal production. It operates mining assets across the Appalachian region, supplying products to global steel manufacturing and industrial clients, with core operations centered on sustainable low-cost metallurgical coal extraction and distribution.
ADMA vs METC — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $121.0M |
| Net Profit | $49.4M | $-13.3M |
| Gross Margin | 63.8% | 15.8% |
| Operating Margin | 45.1% | -12.0% |
| Net Margin | 35.5% | -11.0% |
| Revenue YoY | 18.4% | -27.7% |
| Net Profit YoY | -55.9% | -5468.2% |
| EPS (diluted) | $0.20 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | — | ||
| Q3 25 | $134.2M | $121.0M | ||
| Q2 25 | $122.0M | $153.0M | ||
| Q1 25 | $114.8M | $134.7M | ||
| Q4 24 | $117.5M | $170.9M | ||
| Q3 24 | $119.8M | $167.4M | ||
| Q2 24 | $107.2M | $155.3M | ||
| Q1 24 | $81.9M | $172.7M |
| Q4 25 | $49.4M | — | ||
| Q3 25 | $36.4M | $-13.3M | ||
| Q2 25 | $34.2M | $-14.0M | ||
| Q1 25 | $26.9M | $-9.5M | ||
| Q4 24 | $111.9M | $3.9M | ||
| Q3 24 | $35.9M | $-239.0K | ||
| Q2 24 | $32.1M | $5.5M | ||
| Q1 24 | $17.8M | $2.0M |
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | 15.8% | ||
| Q2 25 | 55.1% | 12.3% | ||
| Q1 25 | 53.2% | 15.2% | ||
| Q4 24 | 53.9% | 20.4% | ||
| Q3 24 | 49.8% | 19.5% | ||
| Q2 24 | 53.6% | 21.0% | ||
| Q1 24 | 47.8% | 19.1% |
| Q4 25 | 45.1% | — | ||
| Q3 25 | 38.0% | -12.0% | ||
| Q2 25 | 35.1% | -9.1% | ||
| Q1 25 | 30.4% | -8.9% | ||
| Q4 24 | 32.6% | 3.7% | ||
| Q3 24 | 33.1% | 1.0% | ||
| Q2 24 | 36.6% | 3.5% | ||
| Q1 24 | 26.7% | 1.9% |
| Q4 25 | 35.5% | — | ||
| Q3 25 | 27.1% | -11.0% | ||
| Q2 25 | 28.1% | -9.1% | ||
| Q1 25 | 23.4% | -7.0% | ||
| Q4 24 | 95.2% | 2.3% | ||
| Q3 24 | 30.0% | -0.1% | ||
| Q2 24 | 29.9% | 3.6% | ||
| Q1 24 | 21.7% | 1.2% |
| Q4 25 | $0.20 | — | ||
| Q3 25 | $0.15 | — | ||
| Q2 25 | $0.14 | — | ||
| Q1 25 | $0.11 | — | ||
| Q4 24 | $0.45 | $0.06 | ||
| Q3 24 | $0.15 | $-0.03 | ||
| Q2 24 | $0.13 | $0.08 | ||
| Q1 24 | $0.08 | $0.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $193.8M |
| Total DebtLower is stronger | $72.1M | $116.3M |
| Stockholders' EquityBook value | $477.3M | $526.9M |
| Total Assets | $624.2M | $849.7M |
| Debt / EquityLower = less leverage | 0.15× | 0.22× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | — | ||
| Q3 25 | $61.4M | $193.8M | ||
| Q2 25 | $90.3M | $28.1M | ||
| Q1 25 | $71.6M | $43.5M | ||
| Q4 24 | $103.1M | $33.0M | ||
| Q3 24 | $86.7M | $22.9M | ||
| Q2 24 | $88.2M | $27.6M | ||
| Q1 24 | $45.3M | $30.5M |
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | $116.3M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | $88.2M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $477.3M | — | ||
| Q3 25 | $431.2M | $526.9M | ||
| Q2 25 | $398.3M | $347.4M | ||
| Q1 25 | $373.4M | $355.2M | ||
| Q4 24 | $349.0M | $362.8M | ||
| Q3 24 | $231.9M | $361.8M | ||
| Q2 24 | $188.3M | $366.1M | ||
| Q1 24 | $153.7M | $372.3M |
| Q4 25 | $624.2M | — | ||
| Q3 25 | $568.7M | $849.7M | ||
| Q2 25 | $558.4M | $674.6M | ||
| Q1 25 | $510.6M | $685.7M | ||
| Q4 24 | $488.7M | $674.7M | ||
| Q3 24 | $390.6M | $645.4M | ||
| Q2 24 | $376.4M | $659.2M | ||
| Q1 24 | $350.9M | $674.0M |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | 0.22× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | 0.24× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $-1.4M |
| Free Cash FlowOCF − Capex | $34.6M | $-17.5M |
| FCF MarginFCF / Revenue | 24.8% | -14.5% |
| Capex IntensityCapex / Revenue | 0.8% | 13.3% |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $-24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | — | ||
| Q3 25 | $13.3M | $-1.4M | ||
| Q2 25 | $21.1M | $-4.3M | ||
| Q1 25 | $-19.7M | $26.0M | ||
| Q4 24 | $50.2M | $15.7M | ||
| Q3 24 | $25.0M | $37.4M | ||
| Q2 24 | $45.6M | $34.4M | ||
| Q1 24 | $-2.2M | $25.2M |
| Q4 25 | $34.6M | — | ||
| Q3 25 | $-1.1M | $-17.5M | ||
| Q2 25 | $18.7M | $-19.8M | ||
| Q1 25 | $-24.4M | $7.6M | ||
| Q4 24 | $47.5M | $5.1M | ||
| Q3 24 | $24.0M | $25.6M | ||
| Q2 24 | $43.6M | $20.3M | ||
| Q1 24 | $-4.6M | $6.5M |
| Q4 25 | 24.8% | — | ||
| Q3 25 | -0.8% | -14.5% | ||
| Q2 25 | 15.3% | -13.0% | ||
| Q1 25 | -21.2% | 5.6% | ||
| Q4 24 | 40.4% | 3.0% | ||
| Q3 24 | 20.0% | 15.3% | ||
| Q2 24 | 40.7% | 13.1% | ||
| Q1 24 | -5.6% | 3.7% |
| Q4 25 | 0.8% | — | ||
| Q3 25 | 10.7% | 13.3% | ||
| Q2 25 | 2.0% | 10.2% | ||
| Q1 25 | 4.1% | 13.7% | ||
| Q4 24 | 2.3% | 6.2% | ||
| Q3 24 | 0.9% | 7.0% | ||
| Q2 24 | 1.9% | 9.1% | ||
| Q1 24 | 2.9% | 10.8% |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | 4.06× | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | 6.21× | ||
| Q1 24 | -0.12× | 12.40× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
METC
| Export Coal Revenues | $73.0M | 60% |
| Domestic Coal Revenues | $48.0M | 40% |
